171 related articles for article (PubMed ID: 32347177)
1. Underestimating the Value of an Intervention: The Case for Including Productivity in Value Assessments and Formulary Design.
Karmarkar T; Graff JS; Westrich K
J Manag Care Spec Pharm; 2020 May; 26(5):652-661. PubMed ID: 32347177
[TBL] [Abstract][Full Text] [Related]
2. For which diseases do broader value elements matter most? An evaluation across 20 ICER evidence reports.
Shafrin J; Dennen S; Pednekar P; Birch K; Bhor M; Kanter J; Neumann P
J Manag Care Spec Pharm; 2021 May; 27(5):650-659. PubMed ID: 33779245
[No Abstract] [Full Text] [Related]
3. HTA and economics in the United States: a systematic review of ICER reports to evaluate trends, identify factors associated with recommendations, and understand implications.
Kruzikas DT; Malone DC; Pham S; Reinsch TK; Akehurst R
J Manag Care Spec Pharm; 2020 Dec; 26(12):1548-1557. PubMed ID: 33251996
[No Abstract] [Full Text] [Related]
4. Examining US commercial health plans' use of The Institute for Clinical and Economic Review's reports in specialty drug coverage decisions.
Chambers JD; Enright DE; Panzer AD; Cohen JT; Ollendorf DA; Neumann PJ
J Manag Care Spec Pharm; 2023 Mar; 29(3):257-264. PubMed ID: 36840954
[No Abstract] [Full Text] [Related]
5. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
6. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis.
Bloudek LM; Pandey R; Fazioli K; Ollendorf DA; Carlson JJ
J Manag Care Spec Pharm; 2021 Aug; 27(8):1046-1055. PubMed ID: 34337994
[No Abstract] [Full Text] [Related]
7. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
[No Abstract] [Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
10. Do Research Groups Align on an Intervention's Value? Concordance of Cost-Effectiveness Findings Between the Institute for Clinical and Economic Review and Other Health System Stakeholders.
Sussman M; Yu JC; Menzin J
Appl Health Econ Health Policy; 2020 Aug; 18(4):477-489. PubMed ID: 31919779
[TBL] [Abstract][Full Text] [Related]
11. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
12. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis.
Hendrix N; Ollendorf DA; Chapman RH; Loos A; Liu S; Kumar V; Linder JA; Pearson SD; Veenstra DL
J Manag Care Spec Pharm; 2018 Dec; 24(12):1210-1217. PubMed ID: 30479197
[TBL] [Abstract][Full Text] [Related]
14. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
15. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
16. Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management.
Bhatt AS; Vaduganathan M; Claggett BL; Fonarow GC; Packer M; Pfeffer MA; Shah SJ; Shen X; Cristino J; McMurray JJV; Solomon SD; Gaziano TA
JAMA Cardiol; 2023 Nov; 8(11):1041-1048. PubMed ID: 37755814
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
[TBL] [Abstract][Full Text] [Related]
18. The evolution of ICER's review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER's reports.
Ronquest NA; Paret K; Gould IG; Barnett CL; Mladsi DM
J Manag Care Spec Pharm; 2021 Nov; 27(11):1601-1612. PubMed ID: 34714108
[No Abstract] [Full Text] [Related]
19. Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.
Whittington MD; McQueen RB; Ollendorf DA; Chapman RH; Kumar VM; Synnott PG; Agboola F; Campbell JD
J Manag Care Spec Pharm; 2019 Jan; 25(1):80-87. PubMed ID: 30589626
[TBL] [Abstract][Full Text] [Related]
20. Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments?
Cohen JT; Silver MC; Ollendorf DA; Neumann PJ
Value Health; 2019 Dec; 22(12):1396-1401. PubMed ID: 31806196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
